Exploring the paucity of the diagnosis: epithelioid hemangioendothelioma of the liver

Presenter: Vasileios Tsagkalidis MD | University of Rochester Background: Hepatic epithelioid hemangioendothelioma (HEH) is a rare vascular tumor unknown etiology and unpredictable natural history. To date, no large-scale studies have been published evaluating this disease due its occurrence. We aimed to use nation-wide, population-based database examine the population characteristics treatment modalities uncommon pathology. Methods: The National Cancer Database was reviewed between 2004-2016 identify patients with HEH undergoing non-palliative therapy. stratified cohort by surgical intervention as wedge/segmental resection, lobectomy/extended lobectomy transplant. clinical demographic were evaluated. Univariate analysis performed variables associated survival. Finally, Kaplan-Meier survival analyses assess overall (OS) modality. Results: identified 229 HEH. median age at diagnosis 55 years. Majority female (61.1%) white (84.3%). received chemotherapy (70.8%), their care an academic center (58%) had Charlson-Deyo score 0 (75%). Only one-third underwent surgery part treatment. 27 liver 18 hepatic 22 30-day 90-day mortality 3%. 5-year 90.5%, 66.5% 81%, respectively (p=0.485) (Figure 1). Age greater than years (HR 2.78, p2: HR 2.76, p=0.011) worse OS. Patients receiving academic/research program or comprehensive community significantly improved 0.39, p=0.008 0.45, p=0.037 respectively) compared integrated network cancer program. Conclusion: This descriptive study represents large proportion hemangioendothelioma. third for significant long-term Older age, higher Asian ethnicity predicted Receiving in disease. international collaboration would probably be beneficial determine optimal